Abstracts

OUTCOMES OF A TELEHEALTH VISIT MODEL TO DELIVER TECOVIRIMAT FOR MPOX IN NYC

Background: A large mpox outbreak in NYC caused significant morbidity beginning in May 2022. Tecovirimat, an anti-Orthopoxvirus medication in the US Strategic National Stockpile available through the Centers for Disease Control and Prevention expanded access investigational new drug protocol, is recommended for patients at risk for or presenting with severe mpox disease. Due to administrative…

MORTALITY LINKED TO HIGHER INFLAMMATION IN PERINATALLY-INFECTED HIV+ KIDS

Background: Mechanisms underlying mortality in some early ART-treated HIV-perinatally infected children remain unclear. The prospective EARTH study (Early Anti-Retroviral treatment in HIV- infected children), enrolled in 6 African centers, 220 perinatally HIV-infected children collecting clinical data and peripheral blood (< 2weeks of age). Trying to identify biomarkers predictive of mortality risk at enrollment visit, we…

SARS-CoV-2 LIVE VIRUS NEUTRALIZATION AFTER FOUR COVID-19 VACCINE DOSES IN PWH ON ART

Background: Limited data exist regarding the immune benefits of fourth COVID-19 vaccine doses in people with HIV (PWH) receiving antiretroviral therapy (ART), particularly given that most have now experienced SARS-CoV-2 infection. We measured the effect of fourth doses on SARS-CoV-2 neutralization in 63 PWH, including 19 SARS-CoV-2-naive and 44 SARS-CoV-2-experienced participants. Methods: Wild-type (WT)-, Omicron-BA.5…

LONG-TERM PROTECTION OF CD4+ T CELLS AGAINST HIV BY ONE-YEAR TREATMENT WITH PONATINIB

Background: Tyrosine kinase inhibitors (TKIs) interfere with the formation and replenishment of HIV reservoir by preserving SAMHD1 antiviral activity in CD4 cells and impeding homeostatic proliferation. We evaluated the persistence of TKI-mediated protective activity against HIV in CD4 from individuals who received one-year treatment with ponatinib against chronic myeloid leukemia (CML). Methods: Nine participants of…

PLASMA ANTIBODY AND N ANTIGEN STATUS PREDICT OUTCOMES IN OUTPATIENTS WITH COVID-19

Background: Reliable biomarkers of COVID-19 severity and outcomes are critically needed for clinical and research applications. We evaluated associations between anti-Spike IgG and SARS-COV-2 nucleocapsid antigen (N Ag) in plasma with clinical outcomes in outpatients with COVID-19. Methods: We used data from 229 non-hospitalized, US-based adults with COVID-19 who enrolled between January and July 2021…